Drug-Free Nanoparticles Halt Triple-Negative Breast Cancer by Reprogramming the Tumor Microenvironment
核心洞察
Technion researchers developed MPsome nanoparticles that inhibit triple-negative breast cancer (搜索) growth without drugs, chemotherapy, or antibodies.
The particles act as a biological decoy, blocking tumor-associated macrophages and enabling the immune system to attack cancer cells naturally.
In preclinical mouse models, efficacy was comparable to approved immunotherapies with no signs of toxicity in vital organs.
A team of researchers at the Technion-Israel Institute of Technology (搜索) has developed a fundamentally new approach to cancer therapy: nanoparticles that suppress aggressive triple-negative breast cancer (搜索) (TNBC) tumors without carrying a single drug molecule. The findings, published in ACS Nano, describe how these engineered particles, called MPsomes (搜索), reprogram the tumor microenvironment by delivering a biological message to immune cells rather than attacking cancer cells directly.
The study was led by Ph.D. candidate Ofri Vizenblit, with assistance from Ph.D. candidate Rawan Mhajne, under the supervision of Assistant Professor Assaf Zinger, head of the Bioinspired Nano Engineering and Translational Therapeutics Laboratory in the Wolfson Faculty of Chemical Engineering.
A Paradigm Shift: Targeting the Microenvironment, Not the Tumor
Triple-negative breast cancer (搜索) accounts for approximately 13% of all breast cancer cases yet is responsible for 40% of deaths, making it one of the most aggressive and difficult-to-treat malignancies. Characterized by rapid progression and high resistance to conventional therapies, TNBC has long represented a significant unmet medical need.
The Technion team's approach departs radically from existing treatment paradigms. Rather than attacking cancer cells themselves, the MPsome nanoparticles target the environment in which tumors thrive. Cancer cells are known to recruit immune cells—particularly macrophages—to their side, effectively hijacking these white blood cells to support tumor growth and suppress immune attack.
The MPsomes (搜索) function as a biological decoy. They compete with immune cells for binding sites in the tumor microenvironment, blocking the access of harmful, tumor-supporting macrophages. This allows the body's natural defenses to recognize and destroy cancer cells without the need for toxic drugs.
“This is a conceptual shift,” the researchers explained. “The therapeutic efficacy does not stem from the release of an active substance, but from the biological information encoded on the surface of the nanoparticle.”
Preclinical Results and Safety Profile
In preclinical experiments using mouse models of triple-negative breast cancer (搜索), the MPsome particles accumulated in exceptionally high concentrations around tumors and inhibited growth with effectiveness comparable to that of currently approved immunotherapies—all without drugs, chemotherapy, or antibodies.
Beyond inhibiting tumor growth, the particles altered the composition of immune cells within the tumor microenvironment: fewer cells that promote tumor development and more cells that attack it. Critically, no signs of toxicity were observed in vital organs.
Manufacturability and Path to the Clinic
A notable practical advantage of the technology is its scalability. The process developed at the Technion enables the production of approximately 20 milliliters of nanoparticles per minute—roughly 1.2 liters per hour. Furthermore, the particle base is composed largely of materials recognized by the FDA as Generally Recognized as Safe (GRAS), a factor that may facilitate the transition to clinical trials and eventual medical use.
“Although we focused here on a specific type of cancer,” concluded Dr. Zinger, “this is a paradigmatic breakthrough that can lead to the development of new therapeutic platforms that are more effective and safer. I sincerely hope we will find the path to bring this invention to the clinic.”
The research remains at the preclinical stage and has so far been tested only in mouse models. The developers plan to seek partners for clinical trials in the near future. Zinger also noted that his group is working on similar nanoparticles for treating neurodegenerative diseases and ovarian cancer.